Martin Erlanson

3.2k total citations
67 papers, 2.3k citations indexed

About

Martin Erlanson is a scholar working on Pathology and Forensic Medicine, Oncology and Genetics. According to data from OpenAlex, Martin Erlanson has authored 67 papers receiving a total of 2.3k indexed citations (citations by other indexed papers that have themselves been cited), including 46 papers in Pathology and Forensic Medicine, 31 papers in Oncology and 16 papers in Genetics. Recurrent topics in Martin Erlanson's work include Lymphoma Diagnosis and Treatment (46 papers), Chronic Lymphocytic Leukemia Research (15 papers) and Viral-associated cancers and disorders (13 papers). Martin Erlanson is often cited by papers focused on Lymphoma Diagnosis and Treatment (46 papers), Chronic Lymphocytic Leukemia Research (15 papers) and Viral-associated cancers and disorders (13 papers). Martin Erlanson collaborates with scholars based in Sweden, Norway and Denmark. Martin Erlanson's co-authors include Hans Hagberg, Göran Roos, Gunilla Enblad, Christer Sundström, Göran Landberg, Bjørn Østenstad, Barbro Linderholm, Harald Holte, Jack Lindh and Jan Delabie and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

Martin Erlanson

67 papers receiving 2.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Martin Erlanson Sweden	25	1.4k	1.2k	543	499	415	67	2.3k
Ryo Ichinohasama Japan	26	1.6k 1.1×	1.2k 1.0×	472 0.9×	488 1.0×	716 1.7×	154	2.9k
Andreas Zettl Germany	30	1.3k 0.9×	1.1k 1.0×	490 0.9×	438 0.9×	301 0.7×	72	2.7k
Theresa Marafioti Germany	9	1.7k 1.2×	993 0.8×	462 0.9×	625 1.3×	221 0.5×	10	2.0k
Ellen D. Remstein United States	26	1.5k 1.1×	985 0.8×	571 1.1×	973 1.9×	828 2.0×	40	2.7k
Rémy Gressin France	26	1.7k 1.2×	1.2k 1.0×	561 1.0×	880 1.8×	379 0.9×	109	2.5k
Enrico Derenzini Italy	25	1.2k 0.8×	766 0.6×	370 0.7×	344 0.7×	405 1.0×	99	1.9k
Irina Bonzheim Germany	26	1.1k 0.8×	948 0.8×	427 0.8×	535 1.1×	376 0.9×	87	1.9k
P.M. Kluin Netherlands	26	1.2k 0.9×	924 0.8×	492 0.9×	671 1.3×	490 1.2×	37	2.2k
Sergio Cogliatti Switzerland	23	1.5k 1.1×	1.1k 0.9×	390 0.7×	796 1.6×	498 1.2×	60	2.2k
Lapo Alinari United States	30	1.7k 1.2×	793 0.7×	518 1.0×	491 1.0×	623 1.5×	115	2.8k

Countries citing papers authored by Martin Erlanson

Since Specialization

Citations

This map shows the geographic impact of Martin Erlanson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Martin Erlanson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Martin Erlanson more than expected).

Fields of papers citing papers by Martin Erlanson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Martin Erlanson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Martin Erlanson. The network helps show where Martin Erlanson may publish in the future.

Co-authorship network of co-authors of Martin Erlanson

This figure shows the co-authorship network connecting the top 25 collaborators of Martin Erlanson. A scholar is included among the top collaborators of Martin Erlanson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Martin Erlanson. Martin Erlanson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Andersson, Anne, Beatrice Melin, Gunilla Enblad, et al.. (2021). High risk of cardiovascular side effects after treatment of Hodgkin’s lymphoma – is there a need for intervention in long-term survivors?. Upsala Journal of Medical Sciences. 126(1). 4 indexed citations

Holte, Harald, Ingrid Glimelius, Magnus Björkholm, et al.. (2019). No excess long‐term mortality in stage I‐IIA Hodgkin lymphoma patients treated with ABVD and limited field radiotherapy. British Journal of Haematology. 188(5). 685–691. 18 indexed citations

Kolstad, Arne, Caroline Stokke, Ayca Muftuler Løndalen, et al.. (2017). A HIGHER AMOUNT OF LILOTOMAB PRE-DOSING INCREASES THE ACTIVITY-ADJUSTED AUC AND HAS A PROTECTIVE EFFECT AGAINST MYELOSUPPRESSION OF LUTETIUM (177LU)-LILOTOMAB SATETRAXETAN IN INDOLENT NHL PATIENTS. Haematologica. 102. 468–469. 1 indexed citations

Kolstad, Arne, B. Bolstad, Caroline Stokke, et al.. (2015). Efficacy and Safety Results of a Phase 1 Study of 177 lu-DOTA-HH1 (Betalutin®) with and without HH1 Pre-Dosing for Patients with Relapsed CD37+ Non-Hodgkin B Cell Lymphoma (NHL). Blood. 126(23). 5118–5118. 1 indexed citations

Pulczynski, Elisa Jacobsen, Outi Kuittinen, Martin Erlanson, et al.. (2014). Successful change of treatment strategy in elderly patients with primary central nervous system lymphoma by de-escalating induction and introducing temozolomide maintenance: results from a phase II study by The Nordic Lymphoma Group. Haematologica. 100(4). 534–540. 79 indexed citations

Kolstad, Arne, Jostein Dahle, Caroline Stokke, et al.. (2014). A Phase I Study of 177 lu-DOTA-HH1 (Betalutin) Radioimmunotherapy for Patients with Relapsed CD37+ Non-Hodgkin's B Cell Lymphoma. Blood. 124(21). 3094–3094. 3 indexed citations

d’Amore, Francesco, Thomas Relander, Grete F. Lauritzsen, et al.. (2012). Up-Front Autologous Stem-Cell Transplantation in Peripheral T-Cell Lymphoma: NLG-T-01. Journal of Clinical Oncology. 30(25). 3093–3099. 386 indexed citations

Wahlin, Björn E., Christer Sundström, Harald Holte, et al.. (2011). T Cells in Tumors and Blood Predict Outcome in Follicular Lymphoma Treated with Rituximab. Clinical Cancer Research. 17(12). 4136–4144. 41 indexed citations

d’Amore, Francesco, Thomas Relander, Esa Jantunen, et al.. (2009). Dose-dense induction followed by autologous stem cell transplant (ASCT) leads to sustained remissions in a large fraction of patients with previously untreated peripheral t-cell lymphomas (PTCLS) - overall and subtype-specific results of a phase II study from the nordic lymphoma group. Lund University Publications (Lund University). 20 indexed citations

10.

Berglund, Mattias, Daniel Molin, Marie Fischer, et al.. (2007). Mast cell infiltration is a favourable prognostic factor in diffuse large B‐cell lymphoma. British Journal of Haematology. 138(1). 68–71. 64 indexed citations

11.

Rosenquist, Richard, Göran Roos, Martin Erlanson, et al.. (2004). Clonally related splenic marginal zone lymphoma and Hodgkin lymphoma with unmutated V gene rearrangements and a 15‐yr time gap between diagnoses. European Journal Of Haematology. 73(3). 210–214. 16 indexed citations

12.

Linderholm, Barbro, J. Andersson, Birgitta Lindh, et al.. (2003). Overexpression of c-erbB-2 is related to a higher expression of vascular endothelial growth factor (VEGF) and constitutes an independent prognostic factor in primary node-positive breast cancer after adjuvant systemic treatment. European Journal of Cancer. 40(1). 33–42. 41 indexed citations

13.

Molin, Daniel, Gunilla Enblad, Anita Gustavsson, et al.. (2003). Early and intermediate stage Hodgkin's lymphoma – report from the Swedish National Care Programme. European Journal Of Haematology. 70(3). 172–180. 11 indexed citations

14.

Amini, Rose‐Marie, Bengt Glimelius, Anita Gustavsson, et al.. (2002). A population‐based study of the outcome for patients with first relapse of Hodgkin's lymphoma. European Journal Of Haematology. 68(4). 225–232. 10 indexed citations

15.

Berglund, Mattias, Richard Rosenquist, Martin Erlanson, et al.. (2002). Clonal development of a blastoid mantle cell lymphoma studied with comparative genomic hybridization. Cancer Genetics and Cytogenetics. 139(1). 38–43. 1 indexed citations

16.

Bauer, Henrik C. F., Clement Trovik, Thor Alvegård, et al.. (2001). Monitoring referral and treatment in soft tissue sarcoma: Study based on 1,851 patients from the Scandinavian Sarcoma Group Register. Acta Orthopaedica Scandinavica. 72(2). 150–159. 97 indexed citations

17.

Amini, Rose‐Marie, Gunilla Enblad, Anita Gustavsson, et al.. (2000). Treatment outcome in patients younger than 60 years with advanced stages (IIB–IV) of Hodgkin's disease: the Swedish National Health Care Programme experience. European Journal Of Haematology. 65(6). 379–389. 16 indexed citations

18.

Erlanson, Martin, et al.. (1998). Flow cytometric quantification of cyclin E in human cell lines and hematopoietic malignancies. Cytometry. 32(3). 214–222. 14 indexed citations

19.

Erlanson, Martin, Göran Landberg, Jack Lindh, & Göran Roos. (1997). Flow Cytometric Evaluation of Proliferating Cell Nuclear Antigen Expression in Human Hematopoietic Malignancies. Acta Oncologica. 36(1). 17–22. 2 indexed citations

20.

Landberg, Göran, Martin Erlanson, Göran Roos, Eng M. Tan, & Carlos A. Casiano. (1996). Nuclear autoantigen p330d/CENP-F: A marker for cell proliferation in human malignancies. Cytometry. 25(1). 90–98. 35 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact